Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study
Salvatore PP, Becerra MC, Wiesch P, Hinkley T, Kaur D, Sloutsky A, Cohen T. Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study. The Journal Of Infectious Diseases 2015, 213: 149-155. PMID: 26092854, PMCID: PMC4676541, DOI: 10.1093/infdis/jiv347.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsCase-control studyKatG Ser315Thr mutationMDR strainsMultiple case householdsResistance mutationsDrug resistance-associated mutationsMycobacterium tuberculosisMultidrug-resistant Mycobacterium tuberculosisSecondary household casesSer315Thr mutationMDR M. tuberculosisMultidrug-resistant tuberculosisMDR Mycobacterium tuberculosisResistance-associated polymorphismsLong-term prevalenceResistance-associated mutationsVivo fitness costsCase-control designEpidemiologic studiesHousehold casesTuberculosisExperimental modelM. tuberculosisMutationsHow could preventive therapy affect the prevalence of drug resistance? Causes and consequences
Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosophical Transactions Of The Royal Society B Biological Sciences 2015, 370: 20140306. PMID: 25918446, PMCID: PMC4424438, DOI: 10.1098/rstb.2014.0306.Peer-Reviewed Original ResearchConceptsPreventative therapyDrug resistanceDrug-sensitive pathogensProphylactic antimicrobial therapyLong-term prevalenceSmall pilot studyActive diseaseOverall prevalenceAntimicrobial therapyPrevalencePilot studyTherapyPopulation-level changesPotential population-level effectsDirect effectLevel of coveragePopulation-level effectsHIVTuberculosisMalariaDiseaseCare